Cargando…

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction

AIMS: Sacubitril/valsartan is a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) with a class-1 guideline recommendation. We assessed the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) on all-cause and cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Michael, Pivodic, Aldina, Käck, Oskar, Costa-Scharplatz, Madlaina, Dahlström, Ulf, Lund, Lars H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849288/ https://www.ncbi.nlm.nih.gov/pubmed/36443599 http://dx.doi.org/10.1007/s00392-022-02124-w

Ejemplares similares

ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2021)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?
por: Kaur, Navjyot, et al.
Publicado: (2021)

Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry
por: Ergatoudes, Constantinos, et al.
Publicado: (2019)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021)

ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)

The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020)

Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J V, et al.
Publicado: (2014)

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
por: Kristensen, Søren L., et al.
Publicado: (2016)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020)

Is there a difference in the effect between the ACEI and ARB on COVID‐19?
por: Chen, Jie, et al.
Publicado: (2020)

ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?
por: Gong, Jin, et al.
Publicado: (2021)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
por: Mogensen, Ulrik M., et al.
Publicado: (2018)

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
por: Yan, Yuling, et al.
Publicado: (2021)

MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB
por: Weber, Martina, et al.
Publicado: (2011)

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020)

Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
por: Khan, Sikandar Hayat, et al.
Publicado: (2020)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

Effects of ACEI and ARB on COVID-19 patients: A meta-analysis
por: Xue, Yang, et al.
Publicado: (2020)

ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021)

Safety of ACEi and ARB in COVID‐19 management: A retrospective analysis
por: Kumar, Sabina, et al.
Publicado: (2022)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Impact of adherence to guideline‐directed therapy on risk of death in HF patients across an ejection fraction spectrum
por: Chen, Xiaojing, et al.
Publicado: (2023)

Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI
por: Ma, Cong, et al.
Publicado: (2012)

COVID-19, ACEI/ARBs, and Gastrointestinal Symptoms: The Jury Is Still Out on the Association
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2021)

ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror
por: Kelleni, Mina T.
Publicado: (2020)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
por: Ma, Jing, et al.
Publicado: (2021)

Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care
por: Hurwitz, Jason T., et al.
Publicado: (2016)

Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19
por: Hamada, Seiji, et al.
Publicado: (2023)

Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register
por: Pastore, Maria Concetta, et al.
Publicado: (2021)

Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study
por: Kang, Jiunn-Horng, et al.
Publicado: (2018)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy
por: Sun, Liping, et al.
Publicado: (2023)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
por: Bhat, Tahir Saleem, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lng406f72g9e7r9t72hqgblv30